04:39 PM EDT, 09/12/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) said interim results from a study of Daybue in patients with Rett syndrome, a neurological developmental disorder, showed symptom improvements.

The results showed 71% to 90% of the 227 patients reported at least one behavioral symptom improvement, the company said Friday in a statement.

The most frequent caregiver-reported improvements were nonverbal communication, alertness, and social interaction, the company said.

Among 33 patients who completed both the baseline and 12-month quality-of-life surveys, the median improvement in their score was 4.6 points, the company said.

The findings reinforce the efficacy and tolerability profile consistent with the Phase 3 trial that supported regulatory approval, the company said.